Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InterMune Launches Esbriet in Germany At Better-Than-Expected Price

This article was originally published in The Pink Sheet Daily

Executive Summary

German pricing for InterMune's IPF drug Esbriet surprises on the upside, but will it last?

You may also be interested in...



Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle

Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.

Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe

German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.

Intermune’s Esbriet Flops In Front Of IQWiG

Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology

Related Content

Topics

UsernamePublicRestriction

Register

PS072768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel